Matthew Sung
Matthew Sung, Ph.D., is Director of ADC Biology & Development at AstraZeneca, recognized globally for his expertise in drug resistance mechanisms. His leadership spans the establishment of ADC-focused research groups and management of multi-disciplinary teams dedicated to combatting resistance in oncology. Dr. Sung’s recent work includes discovering resistance biomarkers, developing and characterizing resistance models, and advancing rational combinations to overcome drug resistance. He has authored influential publications, contributed to regulatory filings, and presented on ADCs & drug resistance at major conferences. His career includes key scientific roles at AstraZeneca and Pfizer, driving innovations in antibody-drug conjugate design and therapeutic strategies.